PDRN Related Substances Analysis: Methods, Standards, and Quality Control Strategies

PDRN (Polydeoxyribonucleotide) related substances analysis is a critical quality control process for evaluating the purity, impurity profile, and molecular integrity of PDRN-based pharmaceutical and cosmetic injectables. This technical article provides a comprehensive overview of PDRN related substances analysis, covering sample types, testing items, analytical methodologies, and regulatory applications to support product development, batch release, and regulatory compliance.

Technical Overview

Polydeoxyribonucleotide (PDRN) is a linear polymer composed of deoxyribonucleotides, primarily extracted and purified from salmon milt (sperm DNA). As a regenerative medicine agent, PDRN promotes tissue repair, wound healing, and angiogenesis through activation of the adenosine A2A receptor signaling pathway. PDRN-based products are widely formulated as sodium salts for injection and have gained significant market presence in aesthetic dermatology, orthopedics, and wound care applications across global markets.

Related substances analysis for PDRN focuses on characterizing process-related and degradation-related impurities, including low-molecular-weight DNA fragments, free nucleotides (dAMP, dGMP, dCMP, dTMP), nucleosides, residual proteins, and residual host genomic DNA. Because the pharmacological activity of PDRN is closely correlated with its chain length and polymerization degree, molecular weight distribution represents a critical quality attribute that must be tightly controlled alongside traditional impurity parameters.

A comprehensive related substances analysis strategy should align with ICH Q3A/Q3B guidelines for impurities, ICH Q6B for biotechnological products, and applicable pharmacopeial or national drug regulatory standards. This testing is essential for supporting Investigational New Drug (IND) submissions, Drug Master Files (DMF), marketing authorization applications, and routine commercial batch release.

Testing Samples

PDRN Active Pharmaceutical Ingredient (API)

Raw PDRN sodium bulk substance in powder or lyophilized form, typically requiring full characterization of purity, molecular weight distribution, related substances, residual proteins, and elemental impurities before formulation processing.

PDRN Sodium Injections

Sterile aqueous solutions for parenteral administration, commonly supplied in pre-filled syringes or ampoules at concentrations ranging from 2.5 mg/mL to 20 mg/mL. These samples require related substances testing combined with sterility, endotoxin, and container closure integrity evaluation.

Cosmetic and Aesthetic Injectables

PDRN-based dermal boosters and skin booster products used in mesotherapy and regenerative aesthetics, which may be presented as standalone PDRN solutions or combination products with hyaluronic acid, amino acids, peptides, or vitamins.

PDRN-Containing Medical Devices

Topical hydrogels, wound dressings, creams, and tissue-engineering scaffolds incorporating PDRN as an active functional component, requiring extractable and leachable assessment in addition to related substances profiling.

Stability Study Samples

PDRN products stored under accelerated and long-term stability conditions (ICH Q1A) for degradation pathway investigation, shelf-life determination, and storage condition optimization.

Testing Items

The related substances analysis panel for PDRN products typically encompasses the following critical quality attributes:

• Related substances and degradation products: quantification of hydrolyzed DNA fragments, free deoxyribonucleotides, and nucleosides against qualified reference standards.
• Molecular weight distribution: determination of weight-average molecular weight (Mw), number-average molecular weight (Mn), and polydispersity index (PDI) to confirm chain length conformity, typically within the 50–1,500 kDa range for therapeutic PDRN.
• Assay and content uniformity: determination of PDRN sodium content as a percentage of labeled claim using validated chromatographic or spectrophotometric methods.
• Residual proteins: measurement of process-derived protein impurities from salmon milt raw material, typically with acceptance limits below 0.1–0.5%.
• Residual host genomic DNA: quantification of high-molecular-weight salmon genomic DNA contamination.
• Bacterial endotoxins: LAL-based testing with limits typically not exceeding 0.5 EU/mg for parenteral products.
• Elemental impurities: ICH Q3D compliant screening of heavy metals including lead, cadmium, mercury, and arsenic.
• Residual solvents: GC-based analysis of process solvents such as ethanol and phenol against ICH Q3C limits.
• Microbiological quality: sterility testing for injectables or bioburden and microbial limits for topical products.
• Physicochemical parameters: appearance, pH, osmolality, clarity, and particulate matter for solution formulations.

Testing Methods

Method selection for PDRN related substances analysis requires consideration of the polymeric nature of the analyte, the lack of chromophores beyond the nucleobase absorbance at 260 nm, and the need for stability-indicating capability.

• Reversed-Phase HPLC (RP-HPLC): separation and quantification of free nucleotides, nucleosides, and small DNA fragments using UV detection at 254–260 nm, enabling individual impurity identification and total impurity summation.
• Size Exclusion Chromatography (SEC-HPLC): coupled with multi-angle light scattering (MALS) or refractive index detection for accurate molecular weight distribution profiling and detection of depolymerized low-molecular-weight species.
• Anion Exchange HPLC (AEX-HPLC): high-resolution separation of PDRN fragments by charge density, providing orthogonal confirmation of size heterogeneity and degradation patterns.
• LC-MS/MS: structural identification and confirmation of unknown impurities, enabling degradation pathway elucidation and impurity qualification studies.
• UV Spectrophotometry: determination of A260/A280 absorbance ratio for rapid purity screening and concentration estimation, with ratios of 1.8–2.0 generally indicating acceptable protein contamination levels.
• Agarose Gel Electrophoresis: qualitative or semi-quantitative visualization of molecular weight distribution and detection of high-molecular-weight genomic DNA contamination.
• Real-Time Quantitative PCR (qPCR): species-specific quantification of residual salmon genomic DNA with high sensitivity down to the femtogram level.
• Bradford or BCA Protein Assay: colorimetric determination of total residual protein content.
• Limulus Amebocyte Lysate (LAL) Assay: kinetic chromogenic or gel-clot endotoxin quantification for injectable products.
• ICP-MS: trace-level quantification of elemental impurities compliant with ICH Q3D requirements.
• Headspace GC-FID: residual solvent determination with sensitivity meeting ICH Q3C option 1 limits.

All analytical methods intended for regulatory submission should be validated in accordance with ICH Q2(R2) guidelines, demonstrating specificity, linearity, accuracy, precision, detection limit, quantitation limit, range, and robustness. Forced degradation studies under acidic, alkaline, oxidative, thermal, and photolytic conditions should be conducted to confirm the stability-indicating capability of the related substances method.

Applications

PDRN related substances analysis supports multiple stages of the product lifecycle across pharmaceutical and cosmetic industries:

• Regulatory registration: generation of quality data packages for IND filings, DMFs, and marketing authorization applications submitted to agencies such as NMPA, MFDS, EMA, and FDA.
• Commercial batch release: routine quality control testing to confirm conformance to approved specifications before product distribution.
• Stability programs: monitoring of related substance growth and molecular weight degradation over time to establish shelf life and storage conditions.
• Process development and optimization: evaluation of extraction, depolymerization, and purification steps to minimize impurity generation and improve batch-to-batch consistency.
• Supplier qualification: comparative quality assessment of PDRN API from different manufacturers to support sourcing decisions.
• Post-market surveillance: investigation of product complaints, out-of-specification results, and generic product equivalence studies.
• Combination product development: compatibility and stability assessment of PDRN with hyaluronic acid, polynucleotide blends, and other functional excipients.

FAQ

What are the main related substances found in PDRN products?

The primary related substances include low-molecular-weight DNA fragments generated by depolymerization, free deoxyribonucleotides and nucleosides from hydrolytic degradation, residual salmon proteins, and residual genomic DNA. These impurities typically originate from raw material processing, thermal degradation during sterilization, or long-term storage instability.

Why is molecular weight distribution critical in PDRN quality control?

The therapeutic efficacy of PDRN depends on its polymer chain length, as molecular weight influences receptor binding affinity, cellular uptake, and pharmacokinetic behavior. Products with molecular weights below the specified range may show reduced biological activity, while excessive high-molecular-weight fractions may affect viscosity and injectability. SEC-HPLC with MALS detection is the recommended technique for this evaluation.

Which regulatory standards govern PDRN related substances analysis?

Currently, PDRN lacks a universal pharmacopeial monograph, so testing strategies typically reference ICH Q3A/Q3B for impurity thresholds, ICH Q2(R2) for method validation, ICH Q5C for stability of biotechnological products, and national standards such as the Korean MFDS guidelines for PDRN injections or the Chinese Pharmaceutical Association specifications for polynucleotide products.

What acceptance criteria are typically applied for related substances?

While specifications vary by product and regulatory jurisdiction, common limits include total related substances not exceeding 5–10%, individual specified impurities not exceeding 2–3%, residual protein below 0.5%, and endotoxins below 0.5 EU/mg for injectable formulations. Justification of specifications should be based on batch historical data, toxicological qualification, and clinical exposure assessment.

How should PDRN samples be handled prior to analysis?

PDRN samples should be stored under recommended conditions, typically refrigerated at 2–8°C and protected from repeated freeze-thaw cycles that may induce depolymerization. Sample preparation should minimize exposure to nucleases, extreme pH, and elevated temperatures, with analysis performed promptly after reconstitution or dilution to prevent artificial degradation.